1. Home
  2. NUVL vs COLB Comparison

NUVL vs COLB Comparison

Compare NUVL & COLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.82

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

COLB

Columbia Banking System Inc.

HOLD

Current Price

$31.45

Market Cap

8.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
COLB
Founded
2017
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
COLB
Price
$100.82
$31.45
Analyst Decision
Strong Buy
Hold
Analyst Count
15
14
Target Price
$135.00
$31.18
AVG Volume (30 Days)
497.6K
3.1M
Earning Date
02-27-2026
01-22-2026
Dividend Yield
N/A
4.74%
EPS Growth
N/A
N/A
EPS
N/A
2.30
Revenue
N/A
$2,151,000,000.00
Revenue This Year
N/A
$32.03
Revenue Next Year
N/A
$2.85
P/E Ratio
N/A
$13.59
Revenue Growth
N/A
17.96
52 Week Low
$55.54
$19.61
52 Week High
$113.02
$32.70

Technical Indicators

Market Signals
Indicator
NUVL
COLB
Relative Strength Index (RSI) 49.64 58.14
Support Level $98.65 $30.75
Resistance Level $106.57 $32.62
Average True Range (ATR) 4.46 0.84
MACD -0.29 0.09
Stochastic Oscillator 47.36 57.73

Price Performance

Historical Comparison
NUVL
COLB

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About COLB Columbia Banking System Inc.

Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.

Share on Social Networks: